INTRODUCTION
Ovarian cancer is the most common cause of cancer death from gynaecological tumours. Ovarian cancer patients initially respond to standard treatments such as cytoreductive surgery and subsequent cisplatin-based chemotherapy. However, there is a distinct problem with this therapy in that ovarian cancer cells are resistant to cisplatin, leading to a survival rate of less than 30 % in patients with ovarian cancers [1] . Thus finding a new low-toxicity and efficient drug to overcome cisplatin resistance would be a major breakthrough.
BetA (betulinic acid) is a naturally occurring triterpenoid that was initially reported to specifically kill melanoma cells by inducing apoptosis [2] and was subsequently shown to have efficacy in neuroectoderm-derived tumours. The anticancer activity of BetA against other types of cancers, such as leukaemia, prostate, ovarian, breast, lung and colon cancer, has also been reported [3] . Moreover, there have been promising studies indicating that BetA not only has inherent single-agent tumoricidal activity against different tumour cells, but also functions co-operatively with other anticancer drugs to trigger apoptosis in chemoresistant neuroblastoma cells [4, 5] . These results indicate that BetA may overcome some forms of drug resistance.
A previous study reported that the extrinsic death receptor pathway does not participate in BetA-induced apoptosis [6] . A decrease in the mitochondrial inner transmembrane potential is associated with BetA treatment, which suggests that the intrinsic mitochondrial pathway is involved in BetA-induced apoptosis. This apoptosis pathway is closely related to the Bcl-2 family of proteins. Anti-apoptotic members sequester multi-domain pro-apoptotic proteins, thereby inhibiting their active role in apoptosis. In contrast, BH3 (Bcl-2 homology domain 3)-only proteins that are considered stress sensors can dissociate Baxlike proteins from their anti-apoptotic sequestrators, thus leading to apoptosis [7] .
The expression of Bcl-2 family proteins is regulated during carcinogenesis [7] , and the expression of both the Bcl-2 and Bcl-xL anti-apoptotic proteins is associated with resistance to antitumour agents such as cisplatin [8] , most notably in ovarian carcinoma [9, 10] . In ovarian carcinoma, the inhibition of the protective function of anti-apoptotic Bcl-2 members can either restore the normal apoptotic process in cancer cells or circumvent resistance to chemotherapy. In this regard, enhanced expression of BH3-only proteins can effectively bind the anti-apoptotic members and prevent the function of these proteins.
Some reports suggest that the BH3-only protein Puma has important roles in p53-dependent and -independent apoptosis in human cancer cells and mediates cell death through the Bcl-2 family proteins Bax/Bak and the mitochondrial pathway [11, 12] . Experiments have revealed that Puma expression is up-regulated in chemosensitive ovarian cells treated with cisplatin, but not in chemoresistant cells treated with cisplatin. Thus the elevation of Puma expression can overcome chemoresistance in ovarian cancer cells [13] .
In the present study, we showed for the first time that BetA can induce apoptosis in cisplatin-resistant ovarian cancer cells. Expression of the BH3-only proteins Puma and Noxa increased following cell death, whereas only Puma siRNA (small interfering RNA) could effectively inhibit Bax translocation, conformational change, oligomerization and the subsequent apoptosis in cisplatin-resistant cells. Moreover, our results demonstrated that Puma expression is independent of p53 regulation in apoptosis. Further experiments revealed that Aktmediated FoxO3a (forkhead box O3a) nuclear translocation and the JNK (c-Jun N-terminal kinase)/c-Jun pathway co-operatively modulate Puma expression. Furthermore, we found that JNK mediates the Akt/FoxO3a pathway, indicating that JNK is an upstream event of BetA treatment-induced apoptosis. These results elucidated the mechanisms of Puma regulation in BetAinduced apoptosis and confirmed that Puma activation is a major molecular event in mediating BetA-induced apoptosis in chemoresistant ovarian cancer cells.
EXPERIMENTAL Reagents
Cisplatin, BetA, LY294001, SP600125, PD98059, SB203580, Hoechst 33342, and the anti-Bax 6A7 monoclonal and anti-actin antibodies were obtained from Sigma. Gene silencing with siRNAs and plasmids siRNA oligonucleotides were created with the following sequences: Puma, 5 -UCUCAUCAUGGGACUCCUG-3 ; Noxa, 5 -CUUCCGGCAGAAACUUCUG-3 ; p53, 5 -CGGCAUGAA-CCGGAGGCCCAU-3 ; and FoxO3a, 5 -ACUCCGGGUCCA-GCUCCAC-3 were purchased from Dharmacon. The constitutively active Akt1 construct [HA (haemagglutinin)-PKB (protein kinase B)-T308D/S473D] was described previously [14] . The dominant-negative c-Jun plasmid (pGFP-TAM67; where GFP is green fluorescent protein) was provided by Dr Jian Zhao (Sichuan University, Chengdu, China). The adenoviral wild-type p53 and LacZ constructs were provided by Dr Frank L. Graham (McMaster University, Hamilton, ON, Canada).
Cell culture and transfection
Cisplatin-sensitive (A2780) and -resistant (A2780/CP) human ovarian cancer cell lines were gifts from Dr Matshela Molepo (Ottawa Regional Cancer Center, Ottawa, ON, Canada) and were incubated in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) FBS (fetal bovine serum) and 1 % penicillin/streptomycin [15] . The COC1/CP cells were also obtained from Dr Molepo. The COC1 and OVCAR-3 cells were obtained from A.T.C.C. No authentication of the cell lines was performed by the authors. The COC1 and OVCAR-3 cells were cultured in suspension with RPMI 1640 medium supplemented with 10 % (v/v) FBS (Hyclone) and 1 % penicillin/streptomycin at 37
• C under 5 % CO 2 . The OVCAR-3 cells were originally obtained from patients who were refractory to platinum-based combination chemotherapy [16] . For general transfection, cells were placed in 6-well plates and then transfected with the appropriate plasmid DNA or siRNA using the protocol described by the manufacturer. Typically, 1 μg of plasmid DNA or siRNA and 4 μl of DMRIE-C reagent (Invitrogen) were used per coverslip. The cells were incubated for 4 h in the transfection mixture, which was then replaced with fresh culture medium. For stable Akt transfection, cells were transfected with the constitutively active Akt1 construct HA-PKB-T308D/S473D as described previously [14] . Positive clones were selected with 1 mg/ml G418 for several weeks.
For adenoviral infection, cells were plated in 6-well plates for 24 h and then infected with adenoviral wild-type p53 at a MOI (multiplicity of infection) of 0, 5, 10 or 20. Infection with an equivalent concentration (MOI) of LacZ was carried out as a proper control. To test the changes in cisplatin sensitivity, infected cells were treated with or without cisplatin (5 μg/ml; 24 h) after a 72-h infection period. The number of apoptotic cells was determined by a Cell Death Detection ELISA (Roche). The p53 protein content was assessed by Western blotting.
Cell viability and apoptosis assay
Ovarian cell viability was assessed by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay in 12 replicates. This procedure has been described previously [17] . The following four methods were used to assess induced apoptotic cell death: detection of DNA fragmentation with the Cell Death Detection ELISA kit; Western blot analysis of caspase activation and PARP cleavage; measurement of apoptotic cells by flow cytometry (Annexin V); and cell staining with Hoechst 33342. The cell death detection ELISA was performed to quantify the apoptotic cells by detecting the histone-associated DNA fragments (mono-and oligo-nucleosomes) generated by apoptotic cells [14] . In brief, the ovarian cells were treated with the experimental compounds and collected to prepare the cytosolic fractions that contained the smaller fragments of DNA. Equal volumes of these cytosolic fractions were incubated in antihistone antibody-coated wells (96-well plates), and the histones of the DNA fragments were allowed to bind to the antihistone antibodies. The peroxidase-labelled mouse monoclonal DNA antibodies were used to localize and detect the bound fragmented DNA using photometric detection with 2,29-azinodi-(3-ethylbenzthiazoline sulfonate) as the substrate, according to the manufacturer's instructions.
Cell fractionation
Mitochondrial and cytoplasmic cell fractions were obtained by differential centrifugation as described previously [18, 19] . Briefly, cells were harvested and resuspended in 3 vol. of hypotonic buffer (210 mM sucrose, 70 mM mannitol, 10 mM Hepes, pH 7.4, and 1 mM EDTA) containing 1 mM PMSF, 50 mg/ml trypsin inhibitor, 10 mg/ml leupeptin, 5 mg/ml aprotinin and 10 mg/ml pepstatin. After gentle homogenization with a Dounce homogenizer, cell lysates were centrifuged at 1000 g for 5 min to remove unbroken cells and nuclei. The supernatant was collected and centrifuged at 10 000 g to pellet the mitochondria-enriched heavy membrane fraction. The supernatant was further centrifuged at 100 000 g to obtain a cytosolic fraction.
Nuclear and cytoplasmic lysates were prepared according to a protocol published previously [20] . Briefly, cells were lysed on ice for 20 min in a buffer containing 10 mmol/l Hepes, pH 7.4, 10 mmol/l KCl, 0.01 mmol/l EDTA, 0.1 mmol/l EGTA, 2 mmol/l dithiothreitol, 10 mmol/l NaF, 1 mmol/l sodium orthovanadate, 30 mmol/l sodium glycerophosphate and protease inhibitors. Nuclei were sedimented by centrifugation, and the supernatant (cytoplasmic fraction) was retained. Nuclei were lysed in the same buffer containing 1 % (v/v) Nonidet P40 and 400 mmol/l NaCl.
RNA isolation and RT (reverse transcription)-PCR
Ovarian cancer cells were treated as described in the Figure legends, and total RNA was isolated with TRIzol ® . The oligonucleotides used for amplification were: p53, 5 -CCT-ACCAGGGCAGCTACGG-3 and 5 -GGAAGACTCCA-GTGGTAATC-3 ; and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), 5 -GAAGGTGAAGGTCGGAGTCA-3 and 5 -CCGACTCTTGCCCTTCGAAC-3 . Total RNA (1 μg) was used for RT-PCR with the Superscript One-step kit (Invitrogen) (20 cycles for p53 and GAPDH). The PCR products, which were 486 bp long for p53 and 260 bp long for GAPDH, were fractionated on a 1 % agarose gel containing ethidium bromide and visualized under UV light.
ChIP (chromatin immunoprecipitation) assay
The ChIP assay was performed using the Chromatin Immunoprecipitation Assay kit (Upstate Biotechnology) according to the manufacturer's protocol. ChIP was performed with 3 μg of anti-c-Jun polyclonal antibody (Pierce) or anti-FoxO3a antibody (Sigma) incubated with Protein G-coated magnetic beads overnight with rotation at 4
• C. The DNA fragments that co-immunoprecipitated with the target proteins c-Jun or FoxO3a were subjected to quantitative real-time PCR analysis using various primer sets. The C T (threshold cycle) value of each sample was normalized to the C T value obtained from the PCR reaction using the corresponding input genomic DNA as a template. Primer sequences for Puma and FoxO3a binding were designed as described previously [21] . Primer sequences were: Puma FoxO3a, 5 -GCCGCCACTGCAGTTAGAG-3 and 5 -AACAGCCGGTTATTGGCC-3 ; and Puma c-Jun, 5 -AG-ATTACCTGCATCTCTTGG-3 and 5 -CCCTGCTCTGGTTT-GGTGAGT-3 .
SDS/PAGE and immunoblotting
SDS/PAGE and immunoblotting were performed as described previously [18] . Briefly, whole cells or the membrane fractions were resuspended in lysis buffer containing Nonidet P40 (10 mM Hepes, pH 7.4, 2 mM EGTA, 0.5 % Nonidet P40, 1 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM dithiothreitol, 50 μg/ml trypsin inhibitor, 10 μg/ml aprotinin and leupeptin) and placed on ice for 30 min. The lysates were centrifuged at 12 000 g for 12 min at 4
• C, and the protein concentration was measured. Equivalent samples (30 μg of protein) were subjected to SDS/PAGE on 12 % gels. The proteins were then transferred on to nitrocellulose membranes and probed with the indicated antibodies followed by the appropriate secondary antibodies conjugated to horseradish peroxidase (KPL). Immunoreactive bands were visualized using enhanced chemiluminescence (Pierce). The molecular sizes of the proteins detected were determined by comparison with pre-stained protein markers (Invitrogen).
Bax conformational change and oligomerization
Bax conformational change analysis was performed as described previously [18] . Cytosolic or mitochondrial fractions were lysed with CHAPS lysis buffer (10 mM Hepes, pH 7.4, 150 mM NaCl and 1 % CHAPS) containing protease inhibitors as described previously [18] . The cell lysates were normalized for protein content, and 250 μg of total protein was incubated with 1 μg of anti-Bax 6A7 monoclonal antibody (Sigma) in 500 μl of CHAPS lysis buffer at 4
• C for 3 h or overnight. Then, 25 μl of Protein Gagarose was added, and the reactions were incubated at 4
• C for an additional 2 h. The beads were washed three times in CHAPS lysis buffer, boiled in loading buffer and the conformationally changed Bax protein in the immunoprecipitates was subjected to SDS/PAGE and immunoblot analysis with anti-Bax polyclonal antibody (Santa Cruz Biotechnology) as described above.
Bax oligomerization was detected as described previously [18] . Cells were washed with conjugating buffer containing 150 mM NaCl, 20 mM Hepes (pH 7.2), 1.5 mM MgCl 2 and 10 mM glucose. Disuccinimidyl suberate in DMSO was added from a 10-fold stock solution to a final concentration of 2 mM [22] . The samples were incubated at room temperature (25
• C) for 30 min with no reduced buffer, and the cross-linker was then quenched by the addition of 1 M Tris/HCl (pH 7.5) to a final concentration of 20 mM and incubation at room temperature for 15 min. The samples were then solubilized in 0.5 % Nonidet P40 lysis buffer without a reducing agent and centrifuged at 12 000 g for 10 min. Bax was detected by Western blotting with an anti-Bax polyclonal antibody (Santa Cruz Biotechnology).
Statistical analysis
Statistical analysis of the differences between the experimental groups was performed using a Student's t test. P < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION

BetA induces apoptosis in chemoresistant ovarian cancer cells
We first examined the apoptotic effect of cisplatin in various cisplatin-sensitive (COC1 and A2780) and -resistant (A2780/CP, COC1/CP and OVCAR-3) human ovarian cancer cells. Apoptosis was detected by the Cell Death Detection ELISA kit with cisplatin treatment (5 μg/ml) at different periods of time. As shown in Figure 1 (A), cisplatin caused apoptosis in chemosensitive ovarian cancer cells, but not in chemoresistant cells. We then investigated the antitumour effect of BetA at different concentrations on ovarian cancer cells. BetA caused a dosedependent reduction in cell viability in cisplatin-sensitive and -resistant cells, showing that the IC 50 value was close to 10 μg/ml ( Figure 1B ). To examine BetA-induced apoptosis, the cells were treated with 10 μg/ml BetA and cell death was confirmed by a DNA fragmentation ELISA assay at various time points. BetA effectively induced apoptosis in all ovarian cancer cells, regardless of their differences in chemo-sensitivity ( Figure 1C ). Western blot analysis confirmed the cell death through the detection of caspase-3 cleavage in chemoresistant cells ( Figure 1D ). These results demonstrated that BetA could initiate cell death in cisplatin-resistant ovarian cancer cells. Thus our findings provided the first evidence that BetA can induce apoptosis in ovarian cancer cells regardless of their chemosensitivity. We also found that BetA enhanced the efficacy of cisplatin in chemoresistant ovarian cancer cells (Supplementary Figure S1 at http://www.BiochemJ.org/bj/444/bj4440291add.htm). These results suggest that, in chemotherapy-based regimens, BetA may be used as a 'sensitizer' that enhances the efficacy of anticancer agents in the inhibition of tumour growth [23] .
As intrinsic mitochondrial pathways play an important role in apoptosis [18, 22] , we then determined whether mitochondria play an important role in BetA-induced apoptosis. The level of cytochrome c release was determined by cell fractionation analysis. Our results revealed that BetA induced cytochrome c release in a time-dependent manner in chemoresistant cells ( Figure 1E ), suggesting that BetA-induced apoptosis is associated with mitochondrial dysfunction.
Expression changes of Bcl-2 family proteins are correlated with the induction of cell death
Mitochondrial dysfunction plays an important role in ovarian cell apoptosis, and the function of Bcl-2 proteins is related to the mitochondrial apoptotic pathway. Previous studies reported that Bcl-2 family proteins are associated with mitochondrial dysfunction and the chemoresistance of cells [24, 25] , and that the BH3-only proteins are important for chemoresistance in ovarian cancer cells [26] .
Several reports have also showed that BetA can modulate the expression levels of Bcl-2 family proteins. For example, BetA treatment resulted in the high expression of the pro-apoptotic Bcl-2 family protein Bax in neuroblastoma, glioblastoma and melanoma cells [27] . Additionally, BetA triggered the upregulation of Mcl-1, another anti-apoptotic Bcl-2 family protein, in melanoma cells, whereas no changes in Mcl-1 levels were detected in squamous cell carcinoma cells [28, 29] . These results suggest that Bcl-2 family proteins have an important role in BetAinduced apoptosis. However, the function of BH3 proteins in ovarian cancer cells treated with BetA is unclear. Therefore, we examined the expression of Bcl-2 family proteins in cisplatinsensitive and -resistant cells after BetA treatment.
We used A2780 and A2780/CP cells as models to study the function of BetA. As shown in Figures 2(A) and 2(B) , pro-apoptotic proteins, such as Bax and Bim, were not significantly changed in all cells treated with BetA at different time points. Anti-apoptotic Mcl-1, Bcl-2 and Bcl-xL proteins also exhibited no major alterations. However, in contrast with other proteins, the expression levels of Puma and Noxa markedly increased after BetA treatment. Meanwhile, Puma and Noxa expression levels were up-regulated in COC1 and COC1/CP cells after BetA treatment (Supplementary Figure S2 at http://www.BiochemJ.org/bj/444/bj4440291add.htm)
At the same time, we observed a Bax conformational change, translocation and oligomerization in ovarian cancer cells after BetA treatment (Figure 2C 
Puma down-regulation by siRNA prevents apoptosis
To identify further the functions of Puma and Noxa, we decided to knock down these proteins using siRNAs in A2780/CP cell lines ( Figure 3A) . Puma siRNA was able to inhibit Puma protein expression, but did not lead to cell death on its own. As described above, a 12 h exposure to BetA induced an obvious apoptotic response in A2780/CP cells. Whereas control siRNA did not modify the response to BetA treatment, we observed a strong decrease in the apoptotic response in cell lines when BetA treatment was combined with Puma siRNA ( Figure 3B Figure  S3 at http://www.BiochemJ.org/bj/444/bj4440291add.htm). In contrast, Noxa siRNA markedly inhibited the expression of Noxa, but had little or no effect on the levels of apoptosis induced by BetA in either cell line ( Figures 3C and 3D , and Supplementary Figure S3) . These results indicated that Noxa is dispensable for BetA-induced apoptosis. The results are in agreement with some previous studies that demonstrated that Noxa has an unimportant role in apoptosis. These studies revealed that forced expression of Noxa was insufficient to trigger neuronal cell apoptosis. Moreover, an experiment using Noxa-deficient mice also indicated that it plays a minor role in the apoptotic pathway [30, 31] . In contrast, several studies revealed that Puma induction strongly correlated with apoptosis, and the ectopic expression of Puma was sufficient to induce apoptosis [30, 31] .
As previous studies revealed that BH3 proteins can directly or indirectly induce Bax activation in apoptosis [7, 11, 12] , we also determined whether the reduction of Puma and Noxa affected Bax activation in apoptosis. Gene silencing of Puma obviously inhibited Bax conformational change, translocation and oligomerization, whereas knockdown of Noxa could not prevent Bax activation (Figures 3E and 3F) . These results further demonstrated that Noxa was not involved in regulating Bax activation and apoptosis. Moreover, these results revealed that Puma mediates Bax activation and the subsequent mitochondrialdependent apoptotic pathway in BetA-treated ovarian cancer cells.
p53 is not involved in Puma activation
We then examined which factor mediates Puma expression. As a previous report indicated that p53 expression is enhanced and p53 transcriptionally triggers Puma expression after stress induction [32] , we wanted to assay whether PUMA is induced by BetA through a p53-dependent mechanism. However, A2780 cells express wild-type p53, whereas A2780/CP cells have mutant p53 [33, 34] . We have detected a single pair missense mutation (G to T) at codon 172 in A2780/CP p53 by PCR amplification and sequence analysis (results not shown). This mutation may lead to a loss of protein function and thereby contribute to cisplatin resistance. Therefore we first detected the status of p53 in A2780 and A2780/CP cells with cisplatin treatment. Our results demonstrated that the expression levels of p53 in A2780 cells increased with cisplatin treatment, whereas p53 induction was unchanged in A2780/CP cells after treatment ( Figure 4A , panels a and b), as described previously [33] . Moreover, cisplatin significantly induced apoptosis in A2780 cells, but not in A2780/CP cells ( Figure 1A) . However, overexpression of wildtype p53 in A2780/CP cells resulted in a concentration (MOI)-dependent increase in cisplatin-induced apoptosis ( Figure 4B , panel a), whereas LacZ expression in A2780/CP cells produced little change in cisplatin-induced apoptosis ( Figure 4B, panel a) . Western blot analysis also showed that p53 expression increased in wild-type p53-infected cells ( Figure 4B, panel b) . Thus the p53 mutation in A2780/CP cells did contribute to cisplatin resistance in the present study.
We then detected p53 expression in cells after treatment with BetA. Western blotting showed that the expression level of p53 had minor changes in all cells regardless of their chemosensitivity ( Figure 4C ). Meanwhile, RT-PCR also revealed that the mRNA levels of p53 changed minimally at different periods of time after BetA treatment ( Figure 4D ).
To further confirm the effect of p53 in Puma expression, we then knocked down p53 with siRNA (p53 siRNA) in ovarian cancer cells. The siRNA was able to inhibit p53 expression, but did not induce caspase-3 cleavage on its own (Figures 4E and 4F, and Supplementary Figure S4 at http://www.BiochemJ. org/bj/444/bj4440291add.htm). We observed that BetA combined with p53 siRNA could not prevent caspase-3 activation in ovarian cancer cells. Importantly, up-regulated Puma expression was invariant in p53 siRNA-transfected chemoresistant cells treated with BetA ( Figure 4F and Supplementary Figure S4 ). These results demonstrate that p53 is not involved in regulating Puma expression even in A2780 cells, which express the wild-type p53. Our results also indicate that BetA-induced apoptosis is independent of p53 activation. In fact, these results are as expected. First, the p53 mutant may lead to inactivity of p53 in apoptosis. Secondly, BetA induced-apoptosis is not associated with the accumulation of wild-type p53 protein [27] . Thus there are other mechanisms that function in modulating Puma expression in ovarian cancer cells.
The Akt pathway does not completely regulate Puma expression
A previous report revealed that Akt dephosphorylation can mediate Puma expression through FoxO3a transcriptional regulation [35] . Moreover, BetA induces Akt dephosphorylation in melanoma cell apoptosis [36] . We speculate that Akt is probably involved in regulating Puma expression in ovarian cancer cells.
Therefore, we measured whether Akt was involved in BetAinduced apoptosis in ovarian cancer cells. As shown in Figure 5 (A), BetA induced the down-regulation of phosphoAkt at Ser 473 in cisplatin-sensitive A2780 cells in a timedependent manner, whereas the expression level of total Akt protein experienced little or no change. Similarly, BetA induced a decrease in phospho-Akt in other cells despite their differences in chemosensitivity.
The decrease in phospho-Akt leads to dephosphorylation and activation of FoxO3a. Active FoxO3a can initiate Puma expression through transcriptional regulation [35] . FoxO3a phosphorylation decreased during the time course with BetA induction, whereas the expression level of total FoxO3a was unchanged ( Figure 5B ). We then determined whether FoxO3a regulates Puma expression in apoptosis. We used the ChIP assay to detect the interactions between FoxO3a and the Puma promoter, as described previously [35] . Our results revealed that FoxO3a can act on the Puma Simultaneously, apoptosis also decreased with FoxO3a siRNA transfection. However, significantly, the reduction of FoxO3a could not completely inhibit Puma expression and apoptosis ( Figure 5C, panel b, and Supplementary Figure S6B) . These results suggest that FoxO3a may not be the sole transcription initiation factor responsible for Puma expression.
To confirm that FoxO3a is a mediator of Akt-dependent Puma-induced apoptosis, it was necessary to detect the nuclear translocation of FoxO3a in chemoresistant cells. Our results showed that FoxO3a translocated from the cytosol to the nucleus and was accompanied by a decrease in phospho-Akt and an increase in Puma expression after BetA treatment. LY294002, the PI3K (phosphoinositide 3-kinase) inhibitor, obviously enhanced nuclear translocation of FoxO3a in cells treated with BetA ( Figure 5D, panel a) . Further experiments indicated that overexpression of Akt1 increased the level of Akt and phospho-Akt ( Figure 5D , panel b, and Supplementary Figure  S6C ), but inhibited nuclear FoxO3a translocation ( Figure 5D , panel b). These results indicated that FoxO3a is a mediator of Akt-dependent Puma expression. It should be noted that the increased protein level of Akt only partially prevented Puma induction. Combined with the results displayed in Figure 5 (C), we speculate that other factors also participate in regulating Puma induction.
JNK potentiates the Akt pathway to regulate Puma expression
To determine which factors within the Akt/FoxO3a pathway mediate Puma expression, we first assayed the activation of some important protein kinases, such as JNK, p38-MAPK (mitogen-activated protein kinase) and ERK, which belong to the MAPK family. These MAPK family proteins have been reported to mediate the Akt/FoxO3a pathway [37, 38] . As shown in Figure 6(A) , the level of phospho-JNK1/2 increased at different periods after BetA treatment with Puma overexpression and dephosphorylation of FoxO3a. The levels of activated p38 (phospho-p38) were also elevated after BetA treatment throughout the time course. A similar profile was found for activated ERK1/2. Western blotting results also indicated that the levels of total JNK, p38 and ERK exhibited no change (results not shown). These results suggest that these kinases are involved in regulating Puma expression and apoptosis after BetA treatment.
To determine which of the kinases activated by BetA affects ovarian cancer cell survival, we treated cells with SP600125, SB203580 and PD98059, which are inhibitors of JNK1/2, p38 and MEK1 (MAP/ERK kinase 1; the upstream activator of ERK1/2) respectively. As shown in Figure 6 (B), treatment of cells with the p38-MAPK inhibitor SB203580 or ERK1 inhibitor PD98059 alone did not elicit cell death at 24 h. Furthermore, PD98059 and SB203580 failed to protect the cells against BetA-induced apoptosis. However, when cells were incubated with SP600125 and BetA, the percentage of cells undergoing apoptosis was dramatically lower than those incubated with BetA alone, indicating that inhibition of JNK1/2 activation protects against the cytotoxic effects of BetA. Figure 6C, panel a) . However, the p38-MAPK inhibitor SB203580 and the ERK1 inhibitor PD98059 had little effect on Puma expression and FoxO3a activation ( Figure 6C, panels b and c) . These results confirm that JNK can regulate the Akt/FoxO3a pathway and induce Puma expression through the Akt/FoxO3a pathway.
Our results indicated that JNK and Akt co-operatively regulate FoxO3a transcriptional activation. However, FoxO3a was obviously not the sole transcription factor to regulate Puma expression. Therefore, another transcriptional factor must participate in triggering the induction of Puma. The JNK downstream target c-Jun is a transcriptional factor that was shown to trigger induction of Puma RNA levels [21] . Thus c-Jun might induce Puma expression by transcriptional regulation in ovarian cancer cells treated with BetA. Our results indeed indicated that c-Jun can act on the Puma promoter as described previously (Supplementary Figure S8 at http://www.BiochemJ.org/bj/444/bj4440291add.htm) [21] . To further confirm that the JNK/c-Jun pathway also mediates Puma activation and subsequent apoptosis, we utilized a dominantnegative mutant of c-Jun, TAM67, which was cloned into the pGFP-C2 plasmid. An immunoblot assay demonstrated that the location of GFP-TAM67 was in the nucleus of transfected cells ( Figure 6D, panel a) , consistent with the location of c-Jun in cells, as described previously [39] . Transfection of GFP-TAM67 indeed reduced Puma expression and caspase cleavage in cells treated with BetA ( Figure 6D, panel b) . Nevertheless, the reduction of c-Jun activity also partially prevented Puma expression. The inhibition of FoxO3a and c-Jun activation prevented Puma expression and apoptosis in cells treated with BetA ( Figure 6D , panels b and c). Therefore our results suggest that c-Jun (regulated by JNK) and FoxO3a (regulated by Akt and JNK) co-ordinately mediate Puma expression and apoptosis in ovarian cancer cells treated with BetA.
At the same time, we also determined whether FoxO3a and cJun can act on the Noxa promoter in our system. We knocked down FoxO3a or c-Jun with siRNA to examine Noxa expression. The reduction in FoxO3a and c-Jun had little effect on Noxa expression (results not shown). These results are in agreement with previous reports [40] [41] [42] . Valis et al. [41] demonstrated that FoxO3a has little effect on Noxa expression. Another previous study revealed that Noxa expression is also independent of c-Jun [42] . Eferl et al. [40] even suggested that c-Jun antagonizes Noxa expression. Of course, we still need to perform further experiments to study the mechanism of Noxa up-regulation and the reasons why Noxa expression is not involved in apoptosis induced by BetA treatment.
Concluding remarks
Our findings can explain how BetA can induce apoptosis in chemoresistant ovarian cancer cells. Our previous study showed that JNK is an upstream event of apoptosis [22] . The experiments described in the present study demonstrate that JNK is also an early response to BetA treatment. JNK can not only mediate the Akt/FoxO3a pathway, but also activate c-Jun in apoptosis. This dual effect of JNK can efficiently trigger Puma activation and subsequent apoptosis in chemoresistant cells (Figure 7 ). The present study also indicates further the importance of BH3-only proteins in chemoresistance, as our and other studies revealed that
Bim is a major determinant of cisplatin resistance in cancer cells [22, 43] .
In conclusion, we have elucidated the molecular mechanisms of BetA-induced apoptosis in cisplatin-resistant ovarian cancer cells and demonstrated that Puma plays a critical role in cisplatin resistance. We provide the first evidence that c-Jun (regulated by JNK) and FoxO3a (regulated by Akt and JNK) co-ordinately mediate Puma expression and apoptosis in chemoresistant ovarian 
